Lyrus, No. 22, 7th Cross, Jaibharath Nagar, Bangalore (2026)

31/12/2025

As 2025 comes to a close, Lyrus extends warm New Year wishes to our partners, customers, and colleagues across the globe.

In 2026, the focus remains on being a trusted CDMO partner of choice for innovative drug delivery solutions, backed by world-class R&D infrastructure and a team with decades of pharmaceutical success.

Lyrus will continue to deliver cost-effective, high-quality formulation development, pilot and exhibit manufacturing, and end-to-end regulatory and analytical support for global markets.

Here’s to a year of breakthrough collaborations, differentiated NDDS and specialty formulations, and sustainable growth together.

Wishing you and your teams a healthy, prosperous, and innovation-filled New Year!

Stabicon Life Sciences Pvt. Ltd. Lyrus Life Sciences Pvt. Ltd Lyrus Life sciences Pvt. Ltd

15/12/2025

Lyrus invites passionate and experienced pharmaceutical professionals to be part of a growing, science-driven organisation.
If you think strategically, design with scientific rigour, and deliver excellence, we would like to meet you.
We are conducting a Walk-In Interview for multiple openings across key functions:
1. Formulation R&D - Master in Pharmacy (Pharmaceutical/industrial pharmacy) - Experiencec: 3-8 years; 7 open positions.
2. Analytical R&D- Master in Pharmaceutical Chemistry/M Sc Chemistry, Experience: 3-8 years; 10 open positions.
3. Technology Transfer - Master in Pharmacy (Pharmaceutics / Industrial Pharmacy); Experience: 8-12 years, 2 open positions.
4. Project Management - M.Pharm / M.Tech /M. Sc. ; Experience: 8-15 years; 3 open positions.
5. Regulatory Affairs - M.Pharm; Experience : 4-8 years, 5 open positions.
6. Business Development - M.Pharm / MTech/MBA, 5 open positions.

At Lyrus, you will work on:
• Global-market formulations
• Complex and differentiated dosage forms
• Regulated markets including EU, US, UK, Australia, South Africa, and LATAM
• Innovation-led pharmaceutical development programs
See more details at the link- https://drive.google.com/file/d/1qlJXglqYZYWUupUKQ3FvOeOtTRtZSkyy/view?usp=sharing
This is an opportunity to contribute to high-impact development projects while accelerating your scientific and professional growth.
Walk-In Interview Details
Date: 20 December 2025
Time: 10:00 AM – 4:00 PM

Venue:
Lyrus Life Sciences Pvt Ltd
R&D Centre, 54A & 54B
Hoskote Industrial Area
Bengaluru – 562122
Please carry:
• Updated resume
• Last 3 months’ salary slips
• Educational certificates
• Aadhaar / PAN card
If collaboration, innovation, and purpose-driven science define your career aspirations, we look forward to meeting you.
For queries, contact the HR team at hr@lyruslife.com

15/12/2025

10,001 strong – and just getting started.
Thank you, Lyrus community
Today, the Lyrus LinkedIn community crossed 10,001 followers – a milestone that reflects the trust of partners, clinicians, scientists, and pharma leaders who believe in science‑driven innovation and reliable CDMO collaboration. As a stand‑alone R&D and CDMO organisation, Lyrus exists to design and deliver differentiated pharmaceutical products and drug delivery platforms that add real value to patients’ lives in regulated markets worldwide.
Our community includes professionals who care deeply about quality, compliance, and scalability – from formulation strategy and analytical development to pilot/exhibit manufacturing and global regulatory pathways. Your engagement motivates our teams in formulation development, analytical services, regulatory, and project management to keep pushing boundaries in NDDS, platform technologies, and complex generics.
Thank you for partnering with Lyrus on this journey. If you are a pharma executive, R&D leader, or business development professional exploring differentiated formulations or CDMO collaborations, follow this page, share it with your network, and start a conversation with us.

12/12/2025

Universal Health Coverage Day: Accelerating "Health for All" Through Strategic Innovation Partnerships
Today, on International Universal Health Coverage Day (December 12), we're reminded of a fundamental truth: everyone deserves access to quality healthcare without financial hardship.
Yet the gap remains significant. 4.5 billion people still lack access to essential health services, and 2 billion people experience financial hardship due to health spending. Bridging this gap demands innovation—not just in science, but in how medicines reach patients globally.
At Lyrus, we believe high-quality CRO and CDMO partnerships are force multipliers in achieving UHC's ambitious vision.
Here's how:
Accelerated Development: By mastering complex formulations and novel dosage forms, we compress timelines from years to months. Faster development = quicker access for patients who can't wait.
Scalable Manufacturing: Our integrated end-to-end capabilities—from formulation to commercial-scale production—enable sustainable, cost-effective manufacturing in diverse geographies, particularly emerging markets where 80% of the global population resides.
Regulatory Excellence: Navigating multi-jurisdictional approvals with precision reduces delays and rejections, lowering the total cost of bringing medicines to market—savings that translate to more affordable therapies.
Technology Transfer & Local Capacity: Through technology partnerships and local innovation, we empower regions to build sustainable pharmaceutical ecosystems, not just dependency on imported medicines.
Our Track Record
In just 9 years, we've evolved from a contract R&D shop to a full-stack pharma producer with 20+ filed patents, multiple regulatory approvals across regulated markets, and a pipeline of differentiated products designed for global reach.
The Insight: UHC isn't built by governments or NGOs alone—it requires strategic, purpose-driven partnerships across the value chain. When CROs and CDMOs operate with both excellence and equity at their core, we unlock the infrastructure to democratize access.
Universal Health Coverage is achievable. It requires innovation, collaboration, and partners committed to making quality medicines accessible everywhere, not just everywhere profitable.
This is the future we're building at Lyrus. We also provide healthcare access to underpreviledged community through our CSR initiative Bothra Foundation. Health for all—starting with the science, scaling with the partnerships.

09/12/2025

Lyrus invites passionate pharma professionals to join our growing R&D-driven organisation. If you think strategically, design with scientific rigour, and deliver excellence, we want to meet you.

We are conducting a Walk-In Interview on 20th December 2025 (10 AM – 4 PM) for multiple openings across key functions including Formulation R&D, Analytical R&D, Technology Transfer, Project Management, Regulatory Affairs, and Business Development.

At Lyrus, you work on global-market formulations, complex dosage forms, regulatory markets (EU, US, UK, Australia, South Africa, LATAM), and innovation-driven development programs. This is an opportunity to shape high-impact pharmaceutical solutions and accelerate your scientific career.
Location:
Lyrus Life Sciences Pvt Ltd,
R&D Centre, 54A & 54B, Hoskote Industrial Area, Bengaluru – 562122.

Candidates are requested to carry their updated resume, last 3 months’ salary slips, educational certificates, and Aadhar/PAN card.
If you believe in the power of collaboration and are ready to build the next chapter of your career, we look forward to meeting you.
For queries, please contact HR at the numbers listed in the poster or write to hr@lyruslife.com
hashtag

09/12/2025

We’re Hiring! | Senior Officer / Executive – Regulatory Affairs

At Lyrus, we are driven by research, technology, and a passion for transforming healthcare. As a global specialty pharma CDMO company, we pride ourselves on innovative drug delivery solutions backed by world-class R&D, cGMP manufacturing, and a leadership team carrying 300+ years of collective expertise.

As we continue to grow, we’re expanding our Regulatory Affairs team.

If you are someone who thrives in compliance, dossier excellence, and global regulatory strategy — this is your opportunity! 👇

🔍 Who We’re Looking For
Qualification: B.Pharm / M.Pharm
Experience: 3–4+ years in Regulatory Affairs
Proven track record in dossier preparation for tablets, capsules, or liquid dosage forms (Modules 1–3)
Exposure to dossier submissions in Europe, GCC, South Africa, or ROW markets is a strong plus.

If you’re detail-oriented, globally engaged, and passionate about regulatory science, we’d love to meet you! See the full job description here: https://lnkd.in/g-_qmABK

Apply via the official application form link below:

https://forms.gle/8eAtV7yquxnCMqU56

📢 Know someone perfect for this role? Tag them or share this post!

03/12/2025

On the International Day of Persons with Disabilities, we reaffirm our commitment to patient‑centric innovation that reduces barriers to safe, effective medicine use.
Accessible oral dose design: We invest in orally disintegrating and 'mouth‑melt tablet's that dissolve without water, supporting patients with dysphagia, neuromuscular conditions, or limited mobility.
Liquid and flexible formulations: Age‑ and ability‑appropriate liquids and suspensions enable precise dose titration for children, older adults, and those unable to swallow conventional tablets.
Usability‑led packaging: By focusing on easy‑open, intuitive packaging and clear labelling, we align with universal design principles and support patients with limited grip strength or visual impairment.
In clinical development, disability inclusion cannot be an afterthought. Evidence shows that people with disabilities are frequently excluded from trials through broad or poorly justified criteria, despite being part of the real‑world treatment population.
Lyrus advocates for and supports more inclusive clinical trial designs that:
Avoid using disability itself as an exclusion criterion when not scientifically justified.
Incorporate reasonable accommodations, accessible materials, and adaptive protocols so that eligible participants with disabilities can take part safely and meaningfully.
Through Think. Design. Deliver., Lyrus is working to ensure that accessibility is built into our formulations, packaging, and development pathways—so that medicines are not only effective in trials, but usable and safe for people with diverse abilities in everyday life.

17/11/2025

National Epilepsy Day: Formulation Innovation for Better Seizure Control
Today, India observes National Epilepsy Day. Epilepsy affects 10 million Indians, yet 70% can achieve seizure control with proper antiepileptic drugs (AEDs).
The challenge? Adherence. Nearly 48% of patients forget doses, 29% experience side effects.
At Lyrus , we develop formulation solutions that improve adherence and outcomes:
Extended-Release Platforms — Our EZYDOZ-XR technology enables once-daily dosing, maintaining stable blood levels and reducing breakthrough seizures.
Rapid Absorption — OROMELT mouth-melting crystals provide fast AED delivery for patients with swallowing difficulties.
Bioavailability Enhancement — Nano-technology platforms optimize AED absorption for narrow therapeutic windows.
Complex Generics — We specialize in bioequivalent AED generics for safe, affordable access across regulated markets.
Adherence is the key to seizure control. Formulation design is the key to adherence.
Through Think. Design. Deliver., Lyrus empowers people living with epilepsy to achieve lasting seizure freedom.
Learn more: www.lyruslife.com

14/11/2025

At Lyrus we believe great results begin with a supportive environment — for therapies, for teams and for people living with chronic conditions. This 14 November, as we mark World Diabetes Day and embrace the theme “Diabetes and well-being at work”, we invite our global partners and colleagues to reflect on how the workplace can become an engine of well-being, not a barrier.
For the millions of working-age adults living with diabetes — approximately 7 in 10 globally — the everyday challenge is not only managing blood glucose, but also navigating stress, stigma, exclusion and environments not designed for their needs. In our industry — the pharmaceutical CDMO sector — we across R&D, formulation and manufacturing must champion inclusive practices that empower teams, support diversity of health needs and deliver science-driven solutions for patients and people alike.

At Lyrus, our tagline sums it up: Think. Design. Deliver.
We think about what well-being means for employees, for partners and for the broader healthcare ecosystem.

We design processes, workplaces and workflows that foster healthy living, equitable support and holistic productivity.

We deliver not only therapeutic outcomes for patients but also an environment where people with diabetes — or at risk of diabetes — can thrive at work.

This World Diabetes Day we call on pharma companies, R&D professionals and workplace leaders to join us: create settings where diabetes care, mental well-being, flexible scheduling and proactive wellness are built-in, not an afterthought. Because truly delivering value means caring for the person behind the work — in labs, offices and production lines.
Let’s work together to ensure that effective medicines meet thriving workplaces.

12/11/2025

World Pneumonia Day: 12 November 2025 – "Every Breath Counts: Stop Pneumonia in Its Tracks"
Pneumonia remains a leading infectious killer worldwide, claiming 2.2 million lives annually. Yet it is preventable and treatable through innovation and access.
At Lyrus, formulation science is at the heart of our mission to combat this global health challenge.
Our Contribution to Pneumonia Solutions:
Advanced Respiratory Therapeutics — Lyrus develops innovative formulations for respiratory infections and anti-inflammatories. Our expertise in complex drug delivery—including sustained-release technology, controlled-release platforms, and bioavailability enhancement—ensures optimal patient outcomes in pneumonia management.
Specialized Dosage Forms — From immediate-release to extended-release oral solids, our proprietary platform technologies (including EZYDOZ-XR for extended therapy profiles) enable formulations tailored to pediatric, geriatric, and dysphasic populations—critical for vulnerable pneumonia patients.
Analytical Excellence — Rigorous analytical method development and validation under international standards ensure rapid drug release testing and quality assurance—key enablers of antimicrobial stewardship and treatment efficacy.
Global Regulatory Pathways — With dossiers submitted to UK MHRA, EU, FDA ANDA, and emerging markets, Lyrus translates formulation innovation into registered products accessible across regulated territories—accelerating time-to-patient for life-saving pneumonia therapies.
Lyrus partners with pharma companies to translate science into quality-assured medicines that strengthen pneumonia prevention and treatment worldwide. Together, we advance global health.
Learn more about our formulation expertise:
www.lyruslife.com

07/11/2025

On National Cancer Awareness Day — November 7, 2025, we unite in the shared mission to fight cancer through awareness, early detection, and equitable care.

This observance reminds us that while cancer continues to claim millions of lives, early diagnosis and timely treatment can save countless others. Instituted by the Ministry of Health, this day also marks the birth anniversary of Marie Curie, whose pioneering research in radioactivity laid the foundation for cancer therapy.

At Lyrus, our purpose goes beyond innovation in labs — it extends into communities.

Through our CSR partnership, Bothra Foundation regularly conducts free cancer screening camps in collaboration with the Karnataka Cancer Society. These camps focus on early detection, risk awareness, and health education, especially in underserved areas where access to screening remains limited.

By bridging science and service, we aim to bring hope and action together — because awareness is only powerful when it leads to prevention and care.

As a Pharma Contract Research and Development Organisation (CDMO), Lyrus continues to partner with pharma innovators, biotechs, and research institutions to:

Think beyond conventional therapy paradigms in oncology.

Design advanced drug delivery systems and formulation strategies for more effective and patient-centric treatments.

Deliver accessible solutions that empower both healthcare professionals and patients.

On this National Cancer Awareness Day, we stand with those battling cancer, those researching its cure, and those reaching out to spread awareness. Together, we can turn fear into focus, and awareness into action.

To collaborate on oncology research, public health initiatives, or CSR partnerships, reach us at bd@lyruslife.com

03/11/2025

Thank You for an Inspiring CPHI Frankfurt 2025:
We extend our sincere thanks to all our clients, partners, and collaborators who connected with us at CPHI Frankfurt 2025. Your insights, ideas, and partnership made this event truly meaningful. CPHI Frankfurt 2025 was a remarkable convergence of ideas, innovation, and collaboration; a powerful reminder of what’s possible when science and partnership come together to shape the future of healthcare.

Over three inspiring days, we connected with global partners, explored new opportunities, and showcased how Lyrus ’s CDMO capabilities and Stabicon’s breakthrough technologies are driving progress in pharmaceutical development. We are inspired by the possibilities ahead and look forward to continuing our journey together; turning ideas into impactful outcomes. Thank you for your continued trust and collaboration. A heartfelt thank you once again for your continued trust and collaboration.

Lyrus

31/12/2025

15/12/2025

15/12/2025

12/12/2025

09/12/2025

09/12/2025

03/12/2025

17/11/2025

14/11/2025

12/11/2025

07/11/2025

03/11/2025

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category